Anti-CD19 Antibody and γδ T-Cell Combination for Tumor Cell Lysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for CD19-expressing hematological cancers, such as chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and acute lymphocytic leukemia (ALL), lack an effective therapeutic agent with improved efficacy.

Innovation Solution

A combination therapy using a CD19-targeting antibody, such as Tafasitamab, enhanced for antibody-dependent cell-mediated cytotoxicity (ADCC), administered with gamma delta T-cells (γδ T-cells) to enhance tumor cell killing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a single anti-CD19 antibody is used for treatment, then the treatment approach is simple, but the therapeutic efficacy is insufficient

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidtreatment approach complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines an anti-CD19 antibody with gamma delta T-cells into a composite therapeutic system. The antibody provides CD19 targeting and ADCC activity, while the T-cells provide cytotoxicity through perforin and granzyme mechanisms, creating synergistic anti-tumor effects that exceed the sum of individual therapies.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The therapeutic formulation integrates multiple functional components (antibody and T-cells) into a composite treatment system where each component contributes specific anti-tumor mechanisms, achieving enhanced overall efficacy through the combination of different therapeutic modalities.

Inventive Principle:

Principle #40Composite materials

2Productivity

If conventional single-agent therapy is used, then the treatment protocol is simple, but tumor cell killing ability is limited

Engineering Contradiction:

Improvetumor cell killing abilityVSAvoidtreatment protocol complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The therapy merges antibody-mediated ADCC with T-cell-mediated cytotoxicity, where the anti-CD19 antibody opsonizes tumor cells for NK cell recognition and gamma delta T-cells directly kill tumor cells through perforin-granzyme pathways, achieving enhanced tumor cell killing capability.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The anti-CD19 antibody acts as an intermediary that bridges the gap between the tumor cell and effector cells, providing Fc-mediated ADCC signals that enhance the cytotoxic activity of gamma delta T-cells against CD19-positive tumor cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy demonstrates increased tumor cell lysis in lymphoma and leukemia cell lines and primary patient-derived samples, showcasing the potential for improved treatment outcomes.

Implementation Method 1

enhanced for antibody-dependent cell-mediated cytotoxicity (ADCC)

Methodology Applied

Scientific EffectAntibody-dependent cell-mediated cytotoxicity (ADCC):

Implementation Method 2

gamma delta T-cells (γδ T-cells) to enhance tumor cell killing

Methodology Applied

Scientific EffectCell-mediated cytotoxicity:

Data Source

PatentEP4051710B1Anti-tumor combination therapy comprising Anti-CD19 antibody and gamma delta t-cells

Publication Date: 2025.11.26 INCYTE CORP

Figure 1
Figure 2
Figure 3

AI summary

The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (Υσ T-cells) for use in the treatment of leukemia or lymphoma.